$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer

2019-12-01

2022-01-01

2022-01-01

122

Study Overview

Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer

To determine the optimal second line treatment strategy in patients with metastatic pancreatic cancer who underwent a therapy with gemcitabine.

The 5-year survival of patients with pancreatic cancer is less than 5%. Despite improvements over the past years with the introduction of FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin and leucovorin) and gemcitabine and nab-paclitaxel, the vast majority will have disease recurrence or progression within 6 months. Single-arm phase II studies have been conducted after gemcitabine-based therapy. Randomized clinical trial data are limited in this setting, but the conclusion up to recently was that there is no superior chemotherapeutic regimen after gemcitabine failure. However, the NAPOLI trial altered the treatment landscape. In this trial, patients with metastatic pancreatic cancer that progressed after treatment with gemcitabine-based chemotherapy received liposomal irinotecan (nal-IRI) either as single agent or in combination with 5-fluorouracil/ leucovorin (5-FU/LV), or 5-FU/LV alone. Patients treated with the combination of nal-IRI plus 5-FU/LV experienced a median survival of 6.1 months versus 4.2 months for the 5-FU/LV group. Recently, two studies on the clinical use of S-1 for pancreatic cancer have been reported from Japan. In the first study, S-1 demonstrated non-inferiority to gemcitabine in overall survival (OS) for advanced pancreatic cancer. In the second study, S-1 showed superiority to adjuvant chemotherapy with gemcitabine in OS. In addition to gemcitabine, S-1 is now regarded as the key drug in the management of pancreatic cancer in Japan. Phase II studies of S-1 in patients with gemcitabine-resistant pancreatic cancer have demonstrated moderate activity with acceptable toxicity. Although there has been no confirmed evidence based on phase III trials, S-1 would be a feasible treatment option in this patient population. Objective: To determine the optimal second line treatment strategy in patients with metastatic pancreatic cancer, whereby the hypothesis is, based on studies conducted in the Asian population, that the combination of S-1 and nal-IRI will be superior compared to 5-FU/ LV and nal-IRI, in terms of progression free survival. Therefore, patients will be randomized, after the optimal dose of S-1 and nal-IRI has been determined in the run in phase, between S-1 in combination with nal-IRI and 5-FU/LV in combination with nal-IRI during the phase II part of the study.

  • Metastatic Pancreatic Cancer
  • DRUG: S1 + Nal-IRI
  • DRUG: Nal-IRI+Leucovorin+5-FU
  • NL64126.018.17

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2019-02-11  

N/A  

2021-01-14  

2019-06-11  

N/A  

2021-01-15  

2019-06-14  

N/A  

2021-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Parallel

Masking:
Single

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: S1 and liposomal irinotecan

S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.

DRUG: S1 + Nal-IRI

  • S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.

DRUG: Nal-IRI+Leucovorin+5-FU

  • Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
EXPERIMENTAL: Liposomal irinotecan, Leucovorin and 5-fluoracil

Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.

DRUG: Nal-IRI+Leucovorin+5-FU

  • Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
Primary Outcome MeasuresMeasure DescriptionTime Frame
DLT of Nal-IRI with S1Dose limiting toxicity (DLT) of nal-IRI when co-administered with fixed dose S1 in patients with metastatic pancreatic cancer36 months
MTD of Nal-IRI with S1Maximum tolerated dose (MTD) of nal-IRI when co-administered with fixed dose S1 in patients with metastatic pancreatic cancer36 months
Progression free survival of NaI-IRI with S1Determination of the efficacy between the treatment arms in terms of progression free survival.36 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Overall survivalTo determine the overall survival (OS) benefit of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma.36 months
Response rate according to RECIST 1.1To determine the response rate according to RECIST 1.1 of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma.36 months
Adverse events according NCI CTC version 4.0To determine the adverse events according to NCI CTC version 4.0 of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma.36 months
Quality of life QoL (QLQ-C30)To determine Quality of life (QoL) benefit of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma using a questionnaire QLQ-C30.Scale ranges 1-4, 1 is very good, 4 is very bad. Higher values represent a worse outcome.36 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: J W Wilmink, MD, PhD

Phone Number: 31 20 5665955

Email: j.w.wilmink@amsterdamumc.nl

Study Contact Backup

Name: E. N. Pijnappel, M.D.

Phone Number: 31 20 5665955

Email: e.n.pijnappel@amsterdamumc.nl

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    Subjects must satisfy all of the following inclusion criteria to be enrolled in the study.
    1. Able to understand and provide written informed consent 2. ≥ 18 years of age 3. Histologically or cytologically confirmed adenocarcinoma of pancreas 4. Documented metastatic disease, according to RECIST 1.1. 5. Previously treated with gemcitabine or gemcitabine containing therapy, or progression within 6 months of adjuvant gemcitabine based treatment 6. Adequate hepatic, renal and hematological function
    Exclusion Criteria:
    A potential subject who meets any of the following criteria will be excluded from participation in this study:
    1. Serum total bilirubin ≥1.5 x ULN (biliary drainage is allowed for biliary obstruction) 2. Severe renal impairment (CLcr ≤ 30 ml/min) 3. Inadequate bone marrow reserves as evidenced by:
    1. ANC ≤ 1,5 x 10 9 /L; or 2. Platelet count ≤ 100 x 10 9 /L; 4. WHO/PS 0-1 5. Any clinically significant disorder impacting the risk-benefit balance negatively per physician's judgment 6. Any clinically significant gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1 7. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) in last 6 months 8. NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically significant abnormal findings 9. Active infection or an unexplained fever >38.5°C (excluding tumor fever), which in the physician's opinion might compromise the patient's health 10. Current use or any use in last two weeks of strong CYP3A-enzyme inducers/inhibitors and/or strong UGT1A inhibitors 11. Known hypersensitivity to any of the components of liposomal irinotecan (Nal-IRI) other liposomal irinotecan formulations, irinotecan, fluoropyrimidines, or leucovorin. 12. Hypersensitivity to any of the active substances (tegafur, gimeracil, and oteracil) 13. Previous treatment with fluoropyrimidine therapy 14. Known dihydropyrimidine dehydrogenase (DPD) deficiency 15. Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use a reliable method of birth control, during therapy and for 3 months following the last dose of liposomal irinotecan (Nal-IRI).
    Treatment within 4 weeks with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • UMC Utrecht
  • Isala
  • Maastricht University Medical Center
  • Vall de Hebron, Barcelona, Spain
  • University Hospital Verona, Italy
  • Odense University Hospital
  • Medical University of Vienna
  • PRINCIPAL_INVESTIGATOR: J W Wilmink, MD, PhD, Ademic Medical Center Amsterdam

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate